Ho sebelisa "Matšoao" a Cellular ho Theha Thepapi e Targeted
Li-CD, tseo hape li tsejoang e le li-antigen tsa CD, ke mefuta e tobileng ea limolek'hule tse fumanehang holim'a lisele tse thusang ho khetholla sele e le 'ngoe ho e' ngoe. Ha e le hantle, li-initials "CD" li bolela "sehlopha sa ho khetholla," lebitso leo lebitso la lona le qalileng ka lona ka 1982.
Le hoja batho ba bang ba ka tseba litlhaloso tsa CD4 le CD8, tse khethollang lisele tsa 'mele tsa ho itšireletsa tse tsejoang e le T-cell , ha li na li-antigen tsa CD tse tsebahalang tse ka tlaase ho 371 tse "tšoaetsang" hoo e batlang e le sele e' ngoe le e 'ngoe ea' mele, .
Seo Lintlha tsa CD li re Bolelang
Har'a lintho tse ling, likarolo tsa CD li sebelisoa ho hlophisa lisele tse tšoeu tsa mali tse hlahisoang ke 'mele ho thusa ho loantša tšoaetso. Lisele tsena ke likarolo tse ka sehloohong tsa tsamaiso ea 'mele ea ho itšireletsa mafung e sebetsang ka thoko ho lemoha, ho lebisa tlhokomelo le ho fokotsa likokoana-hloko tse bakang maloetse.
Ka mohlala, li- CD4 T-cell li bitsoa "lisele tsa mothusi" hobane karolo ea tsona ke ho bontša "CD" T-cell cells "ho bolaea le ho fokotsa pathogen e itseng.
Ka ho utloisisa matla ana, bo-rasaense ba ka sebelisa likarolo tsa CD hore ba se ke ba hlahloba feela boemo ba tšoaetso (e lekantsoe ke keketseho kapa ea fokotseha ka linomoro tsa sele) empa lekanya matla a 'mele oa boitshireletso ba' mele ka boeena. Maemo a mang a kang tšoaetso ea HIV le setho sa 'mele a amana le khatello ea' meleng, e bolelang hore 'mele ha o khone ho itšireletsa ho itšireletsa mafung joalokaha ho pakoa ke ho se be le CD4 T-cell.
Pele ho kenyelletsoa nomoro ea CD, ho hlahloba tšebetso ea motho ea ho itšireletsa mafung ho ne ho le boima le ho feta.
Lintlha tsa CD ho Kankere le Tlhahlobo ea Kankere
Ntle le ho hlahloba tšoaetso le boemo ba 'mele oa ho itšireletsa mafung, li-antigen tsa CD li ka sebelisoa ho bona khōlo e sa tloaelehang ea lisele tse tsejoang e le neoplasme . Li-neoplasms li ka 'na tsa e-ba lihlong (e seng kankere), li bolaeang (kankere), kapa li-precancerous, empa, joaloka sele e' ngoe le e 'ngoe, li na le likarolo tsa CD tseo bo-rasaense ba ka li sebelisang ho li khetholla.
Litokomane tsa CD hase tsa bohlokoa feela ha ho fumanoa kankere, li ka thusa ho tseba hore na ke mefuta efe ea phekolo e ka atlehang le ho bona hore na phekolo e nepahetse joang ka ho hlahloba liphetoho liphatseng tsa CD tse nepahetseng.
Ho feta moo, bafuputsi kajeno ba khona ho etsa mofuta oa protheine e sireletsang, e tsejoang e le monoclonal antibody (mAb) , e lumellanang le CD antigen e itseng. Likokoana-hloko tsena tse nang le clonate li etsisa tse hlahisoang ke 'mele' me li ka sebelisoa ho loantša kankere ka mofuta o mong oa phekolo o tsejoang e le ho thibela immunotherapy .
Ha o kenngoa 'meleng, maAbs a ka sebetsa ka litsela tse sa tšoaneng ho itšetlehile ka moqapi oa bona:
- Ba ka 'na ba tlama letšoao la CD ka lisele tsa kankere le ho li senya.
- Ba ka 'na ba tlama letšoao la CD lisele tsa kankere' me ba thibela bokhoni ba bona ba ho fetola, ho emisa kapa ho liehisa khōlo ea bona.
- Li ka 'na tsa eketsa tlhaselo ea tlhaho ea' mele e khethehileng ho kankere eo.
Ka ntle ho 'mele, maAbs a tloaelehile ho sebelisoa ho hlahloba li-antigen tsa CD ka mali, mahlahahlaha kapa lisele tsa' mele oa metsi.
Ho thibela Immunotherapy bakeng sa Kankere
Li-antibodies tsa monoclonal kajeno li sebelisoa ho tšoara maloetse a mangata a mangata, ho akarelletsa le mathata a mang a bakoang ke ho itšehla thajana le mefuta e itseng ea kankere. Mokhoa oa bona o atlehang o ka fapana, 'me ba bang ba kankere ba arabela hantle ho feta ba bang.
Ha ho boleloa hore, tsoelo-pele ea theknoloji ea liphatsa tsa lefutso e entse hore ho be le palo e ntseng e hōla ea li-immunotherapeutic agents. Ho fapana le chemotherapy ea khale e hlahisang lisele tse potlakileng, tse nang le kankere le tse phetseng hantle, lithethefatsi tsena tse ncha li hlasela feela lisele tse nang le "tag" e itseng ea CD.
Har'a lithethefatsi tseo hona joale li amoheloang ke US Food Drug Administration bakeng sa ho sebelisoa ke kankere ea immunotherapy:
- Adcetris (brentuximab vedotin) e sebelisetsoang ho tšoara Hodgkin lymphoma le aplastic large cell lymphoma
- Arzerra (ofatumumab) e ne e tloaetse ho tšoara kankere e nyenyane ea lymphocytic (SLL) le chronic lymphocytic leukemia (CLL)
- Blincyto (blinatumomab) e sebelisetsoang ho phekola mefuta e meng ea lefu la kankere ea mali (ALL)
- Campath (alemtuzumab) e sebelisetsoang ho tšoara CLL
- Gazyva (obinutuzumab) e sebelisetsoang ho tšoara SLL le CLL
- Herceptin (trastuzumab) e ne e tloaetse ho tšoara kankere e itseng ea matsoele le ea mala
- Kadycla (ado-trastuzumab emtansine) e sebelisetsoang ho phekola mefuta e meng ea kankere ea matsoele
- Keytruda (pembrolizumab) e sebelisetsoang ho tšoara kankere e itseng ea hlooho le molala
- Ontak (denileukin diftitox) e sebelisetsoa ho phekola lymphoma letlalong
- Opdivo (nivolumab) e sebelisetsoang ho tšoara kankere ea matšoafo ea matšoafo le likokoana-hloko tse ling tsa hlooho le molala
- Rituxan (rituximab) e sebelisetsoang ho tšoara mefuta e meng ea e seng Hodgkin lymphoma (NHL)
- Zevalin (ibritumomab tiuxetan) e sebelisetsoang ho tšoara mefuta e meng ea NHL
> Mehloli:
> Mokhatlo oa Kankere oa Amerika. "Likokoana-hloko tsa monoclonal ho tšoara kankere." Atlanta, Georgia; e ntlafalitsoeng ka October 2017.
> Vanneman, R. le Dranoff, G. "Ho kopanya immunotherapy le mekhoa ea ho phekola ea phekolo ea kankere." Kan Rev Kankere. 2012: 12: 237-51. DOI: 10.1038 / nrc3237.